AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening
AccuStem Sciences (OTCQB: ACUT) and EmeritusDX have expanded their strategic partnership to commercialize the MSC test for lung cancer screening. The test analyzes 24 microRNAs to differentiate between high and low-risk lung nodules identified through low-dose computed tomography (LDCT).
The partnership aims to enhance lung nodule stratification accuracy, improve patient outcomes, and reduce healthcare costs. The companies plan to launch the MSC test in US clinics in 2026, targeting the 1.6 million patients diagnosed annually with lung nodules in the United States.
The collaboration will utilize EmeritusDX's CLIA-certified laboratory and commercial infrastructure alongside AccuStem's cancer screening technologies. Both companies will pursue reimbursement strategies to broaden access to the MSC test.
AccuStem Sciences (OTCQB: ACUT) e EmeritusDX hanno ampliato la loro partnership strategica per commercializzare il test MSC per lo screening del tumore polmonare. Il test analizza 24 microRNA per distinguere tra noduli polmonari ad alto e basso rischio individuati tramite tomografia computerizzata a bassa dose (LDCT).
L’obiettivo della collaborazione è migliorare la precisione nella stratificazione dei noduli polmonari, ottimizzare i risultati per i pazienti e ridurre i costi sanitari. Le aziende prevedono di lanciare il test MSC nelle cliniche statunitensi nel 2026, rivolgendosi ai 1,6 milioni di pazienti diagnosticati ogni anno con noduli polmonari negli Stati Uniti.
La collaborazione sfrutterà il laboratorio certificato CLIA e l’infrastruttura commerciale di EmeritusDX insieme alle tecnologie di screening oncologico di AccuStem. Entrambe le aziende perseguiranno strategie di rimborso per ampliare l’accesso al test MSC.
AccuStem Sciences (OTCQB: ACUT) y EmeritusDX han ampliado su alianza estratégica para comercializar la prueba MSC para la detección del cáncer de pulmón. La prueba analiza 24 microARN para diferenciar entre nódulos pulmonares de alto y bajo riesgo identificados mediante tomografía computarizada de baja dosis (LDCT).
La asociación busca mejorar la precisión en la estratificación de nódulos pulmonares, optimizar los resultados para los pacientes y reducir los costos sanitarios. Las empresas planean lanzar la prueba MSC en clínicas de EE.UU. en 2026, enfocándose en los 1.6 millones de pacientes diagnosticados anualmente con nódulos pulmonares en ese país.
La colaboración utilizará el laboratorio certificado CLIA y la infraestructura comercial de EmeritusDX junto con las tecnologías de detección del cáncer de AccuStem. Ambas compañías buscarán estrategias de reembolso para ampliar el acceso a la prueba MSC.
AccuStem Sciences (OTCQB: ACUT)와 EmeritusDX는 폐암 선별을 위한 MSC 검사의 상용화를 위해 전략적 파트너십을 확장했습니다. 이 검사는 저선량 컴퓨터 단층촬영(LDCT)을 통해 발견된 고위험 및 저위험 폐결절을 구분하기 위해 24개의 마이크로RNA를 분석합니다.
이번 파트너십은 폐결절 분류 정확도를 향상시키고, 환자 치료 결과를 개선하며, 의료비용을 절감하는 것을 목표로 합니다. 양사는 2026년 미국 클리닉에서 MSC 검사를 출시할 계획이며, 미국 내 매년 160만 명의 폐결절 진단 환자를 대상으로 합니다.
이번 협력은 EmeritusDX의 CLIA 인증 실험실과 상업 인프라를 활용하고, AccuStem의 암 선별 기술과 결합할 예정입니다. 양사는 MSC 검사 접근성을 넓히기 위해 보험 급여 전략도 추진할 것입니다.
AccuStem Sciences (OTCQB : ACUT) et EmeritusDX ont renforcé leur partenariat stratégique pour commercialiser le test MSC de dépistage du cancer du poumon. Ce test analyse 24 microARN afin de différencier les nodules pulmonaires à haut et faible risque identifiés par tomodensitométrie à faible dose (LDCT).
Ce partenariat vise à améliorer la précision de la stratification des nodules pulmonaires, optimiser les résultats pour les patients et réduire les coûts de santé. Les entreprises prévoient de lancer le test MSC dans les cliniques américaines en 2026, ciblant les 1,6 million de patients diagnostiqués chaque année avec des nodules pulmonaires aux États-Unis.
La collaboration exploitera le laboratoire certifié CLIA et l’infrastructure commerciale d’EmeritusDX, ainsi que les technologies de dépistage du cancer d’AccuStem. Les deux sociétés chercheront à mettre en place des stratégies de remboursement afin d’élargir l’accès au test MSC.
AccuStem Sciences (OTCQB: ACUT) und EmeritusDX haben ihre strategische Partnerschaft zur Kommerzialisierung des MSC-Tests zur Lungenkrebsvorsorge ausgeweitet. Der Test analysiert 24 MicroRNAs, um zwischen Hoch- und Niedrigrisiko-Lungenknoten zu unterscheiden, die mittels Niedrigdosis-Computertomographie (LDCT) erkannt wurden.
Die Partnerschaft zielt darauf ab, die Genauigkeit der Lungenknoten-Stratifizierung zu verbessern, die Patientenergebnisse zu optimieren und Gesundheitskosten zu senken. Die Unternehmen planen, den MSC-Test 2026 in US-Kliniken einzuführen, mit Fokus auf die 1,6 Millionen Patienten, die jährlich in den USA mit Lungenknoten diagnostiziert werden.
Die Zusammenarbeit nutzt das CLIA-zertifizierte Labor und die kommerzielle Infrastruktur von EmeritusDX sowie die Krebs-Screening-Technologien von AccuStem. Beide Unternehmen verfolgen Erstattungsstrategien, um den Zugang zum MSC-Test zu erweitern.
- Strategic partnership secured for MSC test commercialization
- Large addressable market of 1.6 million annual lung nodule patients in the US
- Test supported by clinical evidence published in top-tier journals
- Revenue generation delayed until 2026 launch
- Reimbursement strategy still needs to be established
- Requires regulatory approvals and clinical adoption
LONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, and EmeritusDX, a rapidly growing cancer diagnostics and information company, are pleased to announce the expansion of their strategic partnership to include the commercialization of the MSC test for lung cancer screening. This collaboration aims to enhance the accuracy of lung nodule stratification identified via low-dose computed tomography (LDCT), thereby improving patient outcomes and reducing healthcare costs.
The MSC test analyzes 24 microRNAs to distinguish between high- and low-risk lung nodules, enabling clinicians to guide patients to appropriate care pathways earlier and potentially minimizing unnecessary procedures. Supported by robust clinical evidence published in top tier journals, the test is poised to become a crucial component in lung cancer screening workflows.
Under the expanded agreement, AccuStem and EmeritusDX will embark on operational deployment of the MSC test, with plans for a launch into US clinics in 2026. In parallel, both companies will pursue reimbursement strategies that support broader access to MSC for the 1.6 million patients diagnosed annually with lung nodules in the United States.
“The MSC test represents a significant advancement in lung cancer screening technology,” said Wendy Blosser, CEO of AccuStem Sciences. “With millions of Americans eligible for annual screening, this partnership with EmeritusDX positions us to deliver impactful diagnostic solutions efficiently and at scale.”
Robert Embree, CEO of EmeritusDX, commented, “We are excited to collaborate with AccuStem in expanding access to innovative diagnostics for cancer patients. The MSC test leverages our expertise in molecular testing and strengthens our commitment to delivering high-quality diagnostic services nationwide.”
AccuStem and EmeritusDX anticipate a robust rollout of the MSC test in 2026, leveraging EmeritusDX’s CLIA-certified laboratory and commercial infrastructure and AccuStem’s pioneering approach to cancer screening technologies.
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness”, we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making.
For more information, please visit www.accustem.com.
About EmeritusDX
EmeritusDX is a cancer diagnostic and information company. Our expertise is in delivering actionable clinical information. Within our world-class laboratory, we perform testing that guides the diagnosis and treatment of cancer patients. Our partners include hospital and private pathology laboratories, biotechnology companies, academic institutions, contract research and pharmaceutical development organizations, and more. We understand the dependency on our accurate and timely results and our commitment to excellence in this regard is unwavering.
Forward-Looking Statements
This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. AccuStem Sciences, Inc. assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Investor Contact:
Wendy Blosser
Email: investors@accustem.com
FAQ
When will AccuStem Sciences (ACUT) launch the MSC lung cancer screening test in the US?
How does AccuStem's (ACUT) MSC test work for lung cancer screening?
What is the market size for AccuStem's (ACUT) MSC lung cancer screening test?
What is the purpose of AccuStem's (ACUT) partnership with EmeritusDX?
